We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




A Blood-Based Liquid Biopsy Combined with Machine Learning for Early Lung Cancer Diagnosis

By LabMedica International staff writers
Posted on 05 Oct 2021
A novel liquid biopsy that collects fragments of circulating tumor DNA combined with advanced machine learning technology was able to detect over 90% of lung cancers in samples from nearly 800 individuals with and without the disease.

Investigators at Johns Hopkins Medicine (Baltimore, MD, USA) debuted the field of fragmentomics as the basis for lung cancer diagnosis. More...
Fragmentomics studies the physical properties of circulating cell-free DNA fragments. DNA is packaged abnormally in cancer cells, resulting in abnormal fragment patterns when cancer cells die and release their DNA into the bloodstream. Cell-free DNA fragments in the blood can indicate the presence of cancer and suggest its likely location in the body.

Advanced machine learning (artificial intelligence) technology was used to compare an individual’s cell-free DNA patterns against populations with and without cancer. The technology, called DELFI (DNA evaluation of fragments for early interception), used millions of data points to identify both the presence of cancer and its tissue of origin.

For the current study, the investigators, working with colleagues in Denmark and the Netherlands, first performed genome sequencing of cell-free DNA in blood samples from 365 individuals participating in a seven-year Danish study called LUCAS. They validated the cancer detection model using the DELFI approach on an independent cohort of 385 non-cancer individuals and 46 lung cancer patients.

Results revealed that combining fragmentation features, clinical risk factors, and CEA (carcinoembryonic antigen) levels, followed by CT imaging, detected 94% of patients with cancer across stages and subtypes, including 91% of stage I/II and 96% of stage III/IV, at 80% specificity. Genome-wide fragmentation profiles across nearly 13,000 ASCL1 transcription factor binding sites distinguished individuals with small cell lung cancer from those with non-small cell lung cancer with high accuracy.

“It is clear that there is an urgent, unmet clinical need for development of alternative, noninvasive approaches to improve cancer screening for high-risk individuals and, ultimately, the general population,” said first author Dr. Dimitrios Mathios, a postdoctoral researcher at Johns Hopkins Medicine. “We believe that a blood test, or liquid biopsy, for lung cancer could be a good way to enhance screening efforts, because it would be easy to do, broadly accessible and cost-effective.”

A national clinical trial of the DELFI approach is being carried out by the biotech company Delfi Diagnostics (Baltimore, MD, USA). This trial is using the technique to evaluate 1,700 participants in the United States, including healthy participants, individuals with lung and other types of cancers.

The DELFI lung cancer study was published in the August 20, 2021, online edition of the journal Nature Communications.

Related Links:
Johns Hopkins Medicine
Delfi Diagnostics



Gold Member
Serological Pipets
INTEGRA Serological Pipets
Portable Electronic Pipette
Mini 96
New
Pipette
Accumax Smart Series
New
Blood Glucose Test Strip
AutoSense Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.